Ebola Scare Sends Tekmira Pharmaceuticals Shares Soaring; NPS Pharma Initiates Phase 2a Study Of NPSP795 Print E-mail
By Staff and Wire Reports   
Monday, 04 August 2014 22:37
Below is a look at some of the headlines for companies that made news in the healthcare sector on August 4, 2014.
Shares of Tekmira Pharmaceuticals (NASDAQ: TKMR) are continuing to rise following reports that it will be working with the FDA to develop drugs to fight the Ebola virus.

While the TKM-Ebola Phase 1 study was placed on hold in July, the latest surge in Ebola outbreaks places renewed interest on furthering treatment options over the weekend. The FDA stated it "stands ready" to work with companies developing Ebola treatments.

The FDA's hold means Tekmira can't continue with the trial placed on hold, but doesn't prevent the company from submitting a new study proposal.

If the company were to initiate a new trial in people already infected with Ebola, "the benefit-risk ratio changes completely," according to a one FDA source. "Anything that would shift the risk-benefit to a more favorable outcome could potentially allow the authorization of that study."

In pre-market trading, Tekmira shares were up more than nine percent, a move that follows a nearly 11 percent advance on Friday.


NPS Pharmaceuticals, Inc. (NASDAQ: NPSP)
, a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, has initiated a Phase 2a study to evaluate the safety and tolerability of NPSP795 in adult patients with Autosomal Dominant Hypocalcemia (ADH), an ultra-rare genetic disorder of calcium homeostasis.

ADH is caused by mutations of the calcium-sensing receptor (CaSR) gene that increase the sensitivity of the receptor to serum calcium. NPSP795 is a selective calcium receptor antagonist, which binds to the CaSR and decreases its sensitivity to serum calcium. It’s mechanism of action is believed to restore the normal physiological action of the CaSR and address the underlying molecular defect in ADH to return to normal calcium homeostasis. The company expects to report preliminary top-line data from the study in late 2014 or early 2015.

“NPS Pharma is committed to advancing the understanding of Autosomal Dominant Hypocalcemia (ADH), an ultra-rare genetic disease that can lead to serious renal complications,” said Roger Garceau, MD, FAAP, executive vice president and chief medical officer of NPS Pharma. “This new study is an important step in our exploration of the potential of NPSP795 for the treatment of patients with ADH, who do not have approved treatment options."

Also Monday: 

Apricus Biosciences, Inc. (Nasdaq:APRI)
, a pharmaceutical company focusing on the development and commercialization of novel therapeutics for men's and women's health, today announced that the Company's second quarter financial results will be released with the issuance of its Report on Form 10-Q on Monday, August 11, 2014.

Cellular Dynamics International, Inc. (Nasdaq:ICEL)
today announced that the company will host a webcast and conference call to discuss its financial results for the second quarter ended June 30, 2014.

The Cooper Companies, Inc. (NYSE:COO)
today announced it will release third quarter 2014 financial results on Thursday, September 4, 2014, at 4:00 PM ET.

Ekso Bionics Holdings, Inc. (OTCQB:EKSO)
a robotic exoskeleton company, today announced that, due to a breaking announcement from President Obama, CEO Nathan Harding's interview will be rescheduled to a later date.

The Ensign Group, Inc. (Nasdaq:ENSG)
, the parent company of the Ensign™ Group of skilled nursing, rehabilitative care services, home health and hospice care, assisted living, and urgent care companies, announced today that it has acquired Angeles Home Health Care located in Los Angeles, California.

LipoScience, Inc. (Nasdaq:LPDX) today announced that it will release its second quarter 2014 financial results after the market close on Tuesday, August 12, 2014. An investor conference call will follow on the same day at 4:30 P.M. ET.

Medical Action Industries Inc. (Nasdaq:MDCI), announced today that it will hold a conference call on Monday, August 11, 2014 at 10:00 a.m. (ET) to present its financial results for the quarter ended June 30, 2014.

In response to recent polling conducted by MedAssets (Nasdaq:MDAS) indicating nearly 40 percent of health system C-suite executives find cost reduction strategies a top priority, the company will showcase its full suite of solutions designed to reduce the total cost of care at the AHRMM14 Annual Conference, August 3-6 in Orlando (Booth #601).

MELA Sciences, Inc. (Nasdaq:MELA)
, developer of the MelaFind® system, an optical diagnostic device approved for use in the U.S. and the European Union to assist dermatologists in melanoma diagnosis, will release second quarter 2014 financial results on Wednesday, August 13, after the market close.

Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK)
today announced that the company will host its Second Quarter 2014 Investor Conference Call and webcast at 8:00 a.m., Eastern time, on Monday, August 11.

Prothena Corporation plc (Nasdaq:PRTA)
, a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, today reported financial results for the second quarter and six months ended June 30, 2014 and provided an update on its lead programs.

In a press release issued earlier today by Quotient Limited (Nasdaq:QTNT), please be advised that a reference to second quarter of fiscal 2014 was made in error, appearing in the fifth bullet under the section MosaiQ™ - Key Highlights.

Quotient Limited (Nasdaq:QTNT)
, a commercial-stage diagnostics company, today reported financial results for its fiscal first quarter ended June 30, 2014.

Stereotaxis, Inc. (Nasdaq:STXS)
today reported financial results for the second quarter ended June 30, 2014.

Tauriga Sciences, Inc. (OTCQB:TAUG)
, a diversified life sciences company, has today announced the appointment of Dr. Daniel Hassett as a member of the Company's Scientific and Medical Advisory Board. Dr. Hassett was the Co-Founder and Chairman of the Scientific Advisory Board of Pilus Energy LLC prior to Tauriga's acquisition of wholly-owned subsidiary Pilus Energy on January 28, 2014.

Vision-Sciences, Inc. (Nasdaq:VSCI)
, a leading provider of unique flexible endoscopic products utilizing its proprietary sterile disposable EndoSheath® technology, today announced financial results for the first quarter of fiscal 2015, ended June 30, 2014.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus